Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
Public ClinicalTrials.gov record NCT01364597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
Study identification
- NCT ID
- NCT01364597
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 257 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 28 Days to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2011 (Actual)
- Primary completion
- Feb 3, 2022 (Actual)
- Completion
- Feb 3, 2022 (Actual)
- Last update posted
- Oct 20, 2025
2011 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| N01266 243 | Los Angeles | California | 90027 | — |
| N01266 108 | Gulf Breeze | Florida | 32561 | — |
| N01266 103 | Wellington | Florida | 33470 | — |
| N01266 118 | Chicago | Illinois | 60611 | — |
| N01266 106 | Boston | Massachusetts | 02111 | — |
| N01266 101 | Saint Paul | Minnesota | 55102 | — |
| N01266 113 | Chesterfield | Missouri | 63017 | — |
| N01266 105 | Buffalo | New York | 14222 | — |
| N01266 252 | New York | New York | 10029 | — |
| N01266 104 | Rochester | New York | 14642 | — |
| N01266 237 | Durham | North Carolina | 27710 | — |
| N01266 107 | Cincinnati | Ohio | 45229 | — |
| N01266 111 | Columbus | Ohio | 43205 | — |
| N01266 114 | Pittsburgh | Pennsylvania | 15201 | — |
| N01266 117 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01364597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01364597 live on ClinicalTrials.gov.